Citigroup Trims Stake in Bio-Techne Corp

Biotechnology company's shares see trading activity as major investor reduces position

Mar. 3, 2026 at 1:31am

Got story updates? Submit your updates here. ›

Citigroup Inc. has reduced its stake in Bio-Techne Corp, a biotechnology company, by 33.1% during the third quarter. The firm now owns 197,392 shares of the company's stock, down from 295,235 shares previously held.

Why it matters

This transaction by a major institutional investor like Citigroup could signal a shift in sentiment or outlook for Bio-Techne's business and stock performance. Tracking changes in ownership by large investors provides insights into the market's view of the company's prospects.

The details

According to a recent SEC filing, Citigroup sold 97,843 shares of Bio-Techne during the third quarter. The firm now owns approximately 0.13% of the biotechnology company's outstanding shares, valued at around $10.98 million as of the most recent reporting period.

  • Citigroup reduced its stake in Bio-Techne during the third quarter of 2026.

The players

Citigroup Inc.

A major global financial services company that provides a wide range of banking, investing, and other financial products and services.

Bio-Techne Corp

A biotechnology company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostic, and bioprocessing markets.

Got photos? Submit your photos here. ›

The takeaway

This transaction by a prominent investor like Citigroup could signal a shift in market sentiment around Bio-Techne's prospects, though the reasons behind the stake reduction are not entirely clear from the available information. Investors will likely continue to monitor any further changes in ownership and trading activity around this biotechnology stock.